Skip to content

Study · Observational study · n = 340 · 2026

5 results

Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Month Prospective Cohort Analysis.

Boontoterm P, Sakoolnamarka S, Urasyanandana K

Asian journal of neurosurgery19 Nov 2025

PMID42110924 (opens in a new tab)PMCIDPMC13155915 (opens in a new tab)DOI10.1055/s-0045-1813223 (opens in a new tab)PepBankPUB-42110924
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with moderate TBI and nonoperative ICH, Cerebrolysin use was associated with higher discharge CRS-R scores than standard care alone.

    In plain wordsIn adults with moderate brain injury and brain bleeding, Cerebrolysin use was linked to higher discharge CRS-R scores than standard care alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCRS-R at discharge
    Study

    n = 340

    Comparator
    Standard care alone
    Analysis
    Primary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 mL/day · intravenous · 10 daysAs given in this study (human).

    Measurements

    CRS-R score
    20.3
    Cerebrolysin at discharge
    CRS-R score
    16.4
    standard care alone at discharge
    p value
    0.013
    between groups
    CRS-R reported plus/minus term, type unspecified
    2.7
    Cerebrolysin group at discharge, 20.3 ± 2.7
    CRS-R reported plus/minus term, type unspecified
    2.1
    standard care alone at discharge, 16.4 ± 2.1

    Source sentences

    Summary
    The Cerebrolysin group demonstrated significantly greater improvement in CRS-R scores at discharge (20.3 ± 2.7 vs. 16.4 ± 2.1; p  = 0.013)
    1 context sentence
    Summary · context
    Participants received either standard care plus Cerebrolysin (30 mL/day intravenously for 10 days; n  = 160) or standard care alone ( n  = 180).
  2. 02HumanObservational studyEfficacy outcome

    In adults with moderate TBI and nonoperative ICH, Cerebrolysin use was associated with higher Barthel Index scores than standard care alone.

    In plain wordsIn adults with moderate brain injury and brain bleeding, Cerebrolysin use was linked to higher Barthel Index scores than standard care alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBarthel Index
    Study

    n = 340

    Comparator
    Standard care alone
    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 mL/day · intravenous · 10 daysAs given in this study (human).

    Source sentences

    Summary
    The Cerebrolysin group demonstrated significantly greater improvement in CRS-R scores at discharge (20.3 ± 2.7 vs. 16.4 ± 2.1; p  = 0.013), higher BI, lower mRS scores, and improved 6-month survival (59.4 vs. 27.8%; p  < 0.001).
    1 context sentence
    Summary · context
    Participants received either standard care plus Cerebrolysin (30 mL/day intravenously for 10 days; n  = 160) or standard care alone ( n  = 180).
  3. 03HumanObservational studyEfficacy outcome

    In adults with moderate TBI and nonoperative ICH, Cerebrolysin use was associated with lower mRS scores than standard care alone.

    In plain wordsIn adults with moderate brain injury and brain bleeding, Cerebrolysin use was linked to lower mRS scores than standard care alone.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseModified Rankin Scale
    Study

    n = 340

    Comparator
    Standard care alone
    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 mL/day · intravenous · 10 daysAs given in this study (human).

    Source sentences

    Summary
    The Cerebrolysin group demonstrated significantly greater improvement in CRS-R scores at discharge (20.3 ± 2.7 vs. 16.4 ± 2.1; p  = 0.013), higher BI, lower mRS scores, and improved 6-month survival (59.4 vs. 27.8%; p  < 0.001).
    1 context sentence
    Summary · context
    Participants received either standard care plus Cerebrolysin (30 mL/day intravenously for 10 days; n  = 160) or standard care alone ( n  = 180).
  4. 04HumanObservational studyEfficacy outcome

    In adults with moderate TBI and nonoperative ICH, Cerebrolysin use was associated with higher 6-month survival than standard care alone.

    In plain wordsIn adults with moderate brain injury and brain bleeding, Cerebrolysin use was linked to higher 6-month survival than standard care alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseSix-month survival
    Study

    n = 340

    Comparator
    Standard care alone
    Analysis
    Secondary
    Outcome group
    Mortality · Whole body
    Studied dose
    30 mL/day · intravenous · 10 daysAs given in this study (human).

    Measurements

    survival
    59.4%
    Cerebrolysin at 6 months
    survival
    27.8%
    standard care alone at 6 months
    p value
    < 0.001
    between groups

    Source sentences

    Summary
    The Cerebrolysin group demonstrated significantly greater improvement in CRS-R scores at discharge (20.3 ± 2.7 vs. 16.4 ± 2.1; p  = 0.013), higher BI, lower mRS scores, and improved 6-month survival (59.4 vs. 27.8%; p  < 0.001).
    1 context sentence
    Summary · context
    Participants received either standard care plus Cerebrolysin (30 mL/day intravenously for 10 days; n  = 160) or standard care alone ( n  = 180).
  5. 05HumanObservational studySafety outcome

    In moderate TBI with nonoperative ICH, adverse events did not differ significantly between Cerebrolysin and standard care alone.

    In plain wordsIn patients with moderate brain injury, adverse events did not differ significantly between Cerebrolysin and standard care alone.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeAdverse events
    Study

    n = 340

    Comparator
    Standard care alone
    Outcome group
    Adverse events · Whole body
    Studied dose
    30 mL/day · intravenous · 10 daysAs given in this study (human).

    Source sentences

    Summary
    No significant differences in adverse events were observed between groups.
    1 context sentence
    Summary · context
    Participants received either standard care plus Cerebrolysin (30 mL/day intravenously for 10 days; n  = 160) or standard care alone ( n  = 180).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.